Shell et al. (2008) presented that metformin administration could significantly increase cancer chemosensitivity associated with mTOR inhibition following AMPK activation. Previous studies indicate that dysregulation of AKT is a prominent feature of various tumors including NSCLC (Lee et al., 2002; Liao et al., 2019). In addition, AKT amplification and the mTOR signaling pathway also play an important role in mediating DDP resistance in lung cancer (Feng et al., 2019). This evidence concerns the gene MTOR and non-small cell lung carcinoma.